IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs).
IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 15, 2022 | Corporate Round | — | 1 | Evotec | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Evotec | Yes | Corporate Round |